CAR-T Cells Target Glioblastoma Tumour and Microenvironment

Researchers have identified Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) as a shared antigen on glioblastoma tumor cells and associated myeloid cells, paving the way for a novel dual-targeting immunotherapy. This discovery, published online in Nature on July 1, 2026, details the development and preclinical evaluation of GPNMB-targeted chimeric antigen receptor (CAR-T) cells.

The study employed integrated multi-omic profiling of glioblastoma to pinpoint GPNMB as a critical target. This protein is expressed not only on the surface of cancer cells but also within the tumor microenvironment, particularly on myeloid cells that often contribute to tumor growth and immune evasion. By targeting GPNMB, the new CAR-T cell therapy aims to simultaneously attack the tumor and reprogram the immunosuppressive microenvironment.

In vitro and in vivo experiments demonstrated the therapeutic efficacy of these GPNMB-targeted CAR-T cells. The engineered T cells successfully recognized and eliminated glioblastoma cells. Furthermore, they showed activity against the myeloid cells within the tumor microenvironment, suggesting a mechanism to overcome resistance and enhance the anti-tumor immune response. These findings represent a significant step forward in developing more effective treatments for glioblastoma, a highly aggressive brain cancer with limited therapeutic options.

The research team utilized advanced genomic and proteomic analyses to achieve this breakthrough. The identification of GPNMB as a dual target offers a promising strategy to enhance the potency and durability of CAR-T cell therapy for glioblastoma. Future clinical trials will be necessary to validate these preclinical findings and assess the safety and efficacy of this approach in human patients.